Lords Chloro (LORDSCHLO)
CyclicalScore breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹138.53 |
| Market Cap | ₹396.94 Cr |
| P/E Ratio | 12.58 |
| ROCE | 5.05% |
| ROE | 15.05% |
| Dividend Yield | 0% |
| Profit Growth | 43.1% |
| Debt/Equity | 0.72 |
| Sales Growth | 6.08% |
| Promoter Holding | 74.97% |
| 52-Week Range | ₹108 — ₹233 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹84.54 |
Strengths
- High promoter holding at 74.97% aligns shareholder interests.
- Sales growth of 45.03% and profit growth of 262.99% with a reasonable trailing P/E of 13.43.
- Piotroski F-Score of 7/9 indicates decent recent financial health.
- ROE of 15.05% is respectable, and D/E of 0.73 is not excessive.
Concerns
- ROCE of 5.05% is very low, suggesting weak underlying capital efficiency and pricing power.
- Latest quarter net margin of about 5.3% (₹5 Cr profit on ₹94 Cr sales) leaves little cushion for a downturn.
- No dividend yield; investor returns depend entirely on uncertain reinvestment and growth.
- Price-to-book of 2.50 is rich for a commodity chemical cyclical.
AI Analysis
Let me look at Lords Chloro the way I would any chemical company. A commodity chemical maker is by nature a price-taker, not a franchise. The figures confirm that. Sales grew 45% and profit exploded 263%, which sounds wonderful. But on a base of ₹5 Cr net profit in the latest quarter against ₹94 Cr sales, the net margin is only about 5.3%. Such numbers are common in an upcycle, but you cannot extrapolate them. Trailing P/E is 13.43, not expensive, and the PEG of 0.09 is almost absurdly low. But when I see ROCE of only 5.05%, I know the business is not earning a great return on the capital it uses. The 15.05% ROE is partly powered by leverage; D/E of 0.73 is manageable but not negligible. Book value is ₹59.98, so at ₹149.78 I am paying 2.5 times book for a business without pricing power. That is not a margin of safety. On the positive side, promoter holding of 74.97% means owners are in the boat with me, and a Piotroski score of 7/9 suggests recent financial health. There is no dividend, so as a minority shareholder I must rely solely on the company reinvesting at high returns. So far, returns are not compelling. If sales growth continues and margins strengthen, perhaps the market will recognize value. But Graham would tell you to avoid paying up for earnings that can disappear when commodity prices crack. I would want to see several years of evidence, not one spectacular jump. This is a possible cyclical winner, not a compounder, and I want a larger discount before committing.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer